Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 19/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349309 | 1.00 | NR1H4 (0.73) | NR1H4KCNH2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2346163 | 1.00 | NR1H4 (0.73) | NR1H4KCNH2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2347146 | 1.00 | NR1H4 (0.73) | NR1H4KCNH2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2349304 | 1.00 | NR1H4 (0.73) | NR1H4KCNH2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2347888 | 1.00 | NR1H4 (0.73) | NR1H4KCNH2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2346157 | 1.00 | NR1H4 (0.73) | NR1H4KCNH2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2343538 | 1.00 | NR1H4 (0.73) | NR1H4KCNH2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2346151 | 1.00 | NR1H4 (0.73) | NR1H4KCNH2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2351414 | 1.00 | NR1H4 (0.73) | NR1H4KCNH2CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2343535 | 1.00 | NR1H4 (0.73) | NR1H4KCNH2CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222645-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | HOFFMANN LA ROCHE (CH) | 2013-03-20 | — | — | EP | claimed |
| US-7825258-B2 | Methyl-benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | claimed |
| EP-2222645-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-09-01 | — | — | EP | claimed |
| WO-2009062874-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-22 | — | — | WO | claimed |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-05-21 | — | — | US | claimed |
| EP-2222645-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | HOFFMANN LA ROCHE (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8008503-B2 | Methyl-benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100331371-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | BENSON GREGORY MARTIN | 2010-12-30 | — | — | US | disclosed |
| US-7825258-B2 | Methyl-benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HDAC10, CYP3A4, ECI1 | NR1H4 217/4885KCNH2 652/4885CYP3A4 2/4885 |
| US-20100331371-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HDAC10, CYP3A4, ECI1 | NR1H4 217/4885KCNH2 652/4885CYP3A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.